• 主题
高级搜索  >
历史搜索 清空历史
首页> 外国专利> NOVEL BIOMARKER OF TUMOR NEOGENESIS BLOOD VESSEL VASCULAR ENDOTHELIAL CELL AND CANCER THERAPEUTIC AGENT WHICH MAKES THE SAME TARGET

NOVEL BIOMARKER OF TUMOR NEOGENESIS BLOOD VESSEL VASCULAR ENDOTHELIAL CELL AND CANCER THERAPEUTIC AGENT WHICH MAKES THE SAME TARGET

机译：具有相同靶点的肿瘤新生血管血管内皮细胞和癌治疗剂的新生物标志物

页面导航
  • 摘要
  • 著录项
  • 相似文献

摘要

PPROBLEM TO BE SOLVED: To provide a neovascularization inhibitor in which mechanism of neovascularization is clarified further, which is based on new mechanism, and is useful for treating tumor. PSOLUTION: YB-1 specifically develops in a tumor neogenesis blood vessel, and contributes to the growth factor dependence-proliferation of a vascular endothelial cell. Therefore, expression of YB-1 is inhibited, whereby proliferation of a vascular endothelial cell is controlled, and neovascularization can be inhibited. Since YB-1 specifically develops in a vascular endothelial cell of a tumor neogenesis blood vessel, when expression of YB-1 is inhibited, proliferation of a vascular endothelial cell of a tumor neogenesis blood vessel (namely neovascularization in a tumor tissue) can be inhibited selectively. Moreover, since YB-1 involves drug tolerance or proliferation of a tumor cell, expression of YB-1 is inhibited, it becomes possible to inhibit proliferation of both a tumor cell and a vascular endothelial cell of a tumor neogenesis blood vessel. PCOPYRIGHT: (C)2011,JPO&INPIT
机译：<待解决的问题：提供一种新血管生成抑制剂，其中新的血管生成机理进一步阐明，其基于新的机理，并且可用于治疗肿瘤。

解决方案：YB-1在肿瘤新生血管中特异性发育，并有助于血管内皮细胞的生长因子依赖性增殖。因此，抑制了YB-1的表达，从而控制了血管内皮细胞的增殖，并且可以抑制新血管形成。由于YB-1在肿瘤新生血管的血管内皮细胞中特异性发育，因此当抑制YB-1的表达时，可以抑制肿瘤新生血管的血管内皮细胞的增殖（即肿瘤组织中的新生血管形成）。有选择地。此外，由于YB-1涉及药物耐受性或肿瘤细胞的增殖，因此抑制了YB-1的表达，因此可以抑制肿瘤新生血管的肿瘤细胞和血管内皮细胞的增殖。

版权：（C）2011，日本特许厅＆INPIT

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号